Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Inclusion criteria:

1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to
screening

2. Treatment naive or confirmed prior treatment relapse or partial response following
treatment with interferon and ribavirin

3. Age 18 to 70 years

4. HCV RNA (Hepatitis C Virus RiboNucleic Acid) = 1,000 IU/mL at screening

5. Liver biopsy or fibroscan to exclude cirrhosis

Exclusion criteria:

1. Hepatitis C Virus (HCV) infection of mixed genotype; Hepatitis B Virus (HBV) or
Human Immunodeficiency Virus (HIV) co-infection

2. Evidence of acute or chronic liver disease due to causes other than chronic HCV
infection,

3. Decompensated liver disease, or history of decompensated liver disease,

4. Body weight < 40 or > 125 kg,

5. Clinical evidence of significant or unstable cardiovascular disease, chronic
pulmonary disease, history or evidence of retinopathy or clinically significant
ophthalmological disorder

6. Pre-existing psychiatric condition that could interfere with the subject's
participation in and completion of the study

7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or glucose 6
phosphate dehydrogenase deficit)

8. Hemoglobin < 12 g/dL for women and < 13 g/dL for men

9. Patients who have been previously treated with at least one dose of any antiviral or
immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic
HCV infection